China Biologic Products (CBPO) Lifted to “Hold” at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of China Biologic Products (NASDAQ:CBPO) from a strong sell rating to a hold rating in a report published on Monday.

According to Zacks, “China Biologic Products, Inc., through its indirect majority-owned subsidiary, is principally engaged in the research, development, production, manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. Its subsidiary, Shandong Taibang Biological Products Co. Ltd., operates from its manufacturing facility located in Taian City, Shandong Province. The Company’s principal products include its approved human albumin and immunoglobulin products. These human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases. “

A number of other equities research analysts also recently issued reports on CBPO. BidaskClub downgraded shares of China Biologic Products from a buy rating to a hold rating in a report on Thursday, December 13th. ValuEngine raised shares of China Biologic Products from a sell rating to a hold rating in a report on Thursday, November 1st. Finally, Morgan Stanley downgraded shares of China Biologic Products from an overweight rating to an equal weight rating and set a $84.00 price target on the stock. in a report on Monday, November 5th. Six research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus price target of $95.33.

CBPO traded down $0.70 during trading on Monday, hitting $77.09. 1,325 shares of the company traded hands, compared to its average volume of 111,650. The firm has a market cap of $2.48 billion, a P/E ratio of 15.56, a PEG ratio of 4.66 and a beta of 1.40. China Biologic Products has a one year low of $60.08 and a one year high of $107.44.

China Biologic Products (NASDAQ:CBPO) last released its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported $0.96 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.09 by ($0.13). The business had revenue of $119.10 million for the quarter, compared to analysts’ expectations of $122.00 million. China Biologic Products had a net margin of 15.50% and a return on equity of 11.44%. China Biologic Products’s revenue for the quarter was up 19.6% compared to the same quarter last year. During the same period last year, the company earned $1.32 earnings per share. Equities analysts predict that China Biologic Products will post 3.43 EPS for the current year.

Several institutional investors have recently made changes to their positions in CBPO. Hsbc Holdings PLC raised its stake in China Biologic Products by 110.8% in the third quarter. Hsbc Holdings PLC now owns 1,484,839 shares of the biopharmaceutical company’s stock valued at $118,785,000 after purchasing an additional 780,455 shares in the last quarter. Capital World Investors purchased a new stake in China Biologic Products in the third quarter valued at approximately $27,464,000. York Capital Management Global Advisors LLC raised its stake in China Biologic Products by 41.1% in the third quarter. York Capital Management Global Advisors LLC now owns 1,167,643 shares of the biopharmaceutical company’s stock valued at $93,411,000 after purchasing an additional 339,905 shares in the last quarter. Greenwoods Asset Management Ltd purchased a new stake in China Biologic Products in the third quarter valued at approximately $19,600,000. Finally, FMR LLC raised its stake in China Biologic Products by 91.4% in the third quarter. FMR LLC now owns 448,094 shares of the biopharmaceutical company’s stock valued at $35,847,000 after purchasing an additional 213,994 shares in the last quarter. 48.63% of the stock is currently owned by hedge funds and other institutional investors.

About China Biologic Products

China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.

See Also: Short Selling Stocks, A Beginner’s Guide

Get a free copy of the Zacks research report on China Biologic Products (CBPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

ASV  Rating Increased to Hold at Zacks Investment Research
ASV Rating Increased to Hold at Zacks Investment Research
Aptose Biosciences  Rating Lowered to Hold at Zacks Investment Research
Aptose Biosciences Rating Lowered to Hold at Zacks Investment Research
Analysts Anticipate Riverview Bancorp, Inc.  to Announce $0.18 Earnings Per Share
Analysts Anticipate Riverview Bancorp, Inc. to Announce $0.18 Earnings Per Share
Spire Healthcare Group PLC  Given Consensus Recommendation of “Hold” by Analysts
Spire Healthcare Group PLC Given Consensus Recommendation of “Hold” by Analysts
Zacks Investment Research Downgrades bluebird bio  to Sell
Zacks Investment Research Downgrades bluebird bio to Sell
China Biologic Products  Lifted to “Hold” at Zacks Investment Research
China Biologic Products Lifted to “Hold” at Zacks Investment Research


Leave a Reply

© 2006-2019 Ticker Report